• A. Gaw
  • C. J. Packard
  • J. Shepherd
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 109)


The fibric acid derivatives, or fibrates, have, until recently, been the most widely used lipid-lowering drugs in clinical practice. In the UK, for the year ending June 1990, the fibrates available at that time (bezafibrate, gemfibrozil and clofibrate) constituted 62% of all prescribed items for hyperlipidaemia. In the same period, bezafibrate was the most widely prescribed lipid-lowering drug (O’Brien 1991). In the US, from 1984–1987, gemfibrozil held first place in the ranking of lipid-lowering drugs in terms of number of prescriptions written and was only overtaken in 1988, after the introduction of lovastatin (Wysowski et al. 1990).


Familial Hypercholesterolaemia Fibric Acid Derivative Helsinki Heart Study Fractional Catabolic Rate Fibrate Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abshagen U, Bablok W, Koch K, Lang PD, Schmidt HAE, Senn M, Stork H (1979) Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 16: 31–38PubMedCrossRefGoogle Scholar
  2. Angelin B, Einarsson K, Leijd B (1984) Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. Eur J Clin Invest 14: 73–78PubMedCrossRefGoogle Scholar
  3. Austin MA, Krauss RM (1986) Genetic control of low density lipoprotein subclasses. Lancet 2: 592–595PubMedCrossRefGoogle Scholar
  4. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260: 1917–1921PubMedCrossRefGoogle Scholar
  5. Austin MA, King MC, Vranizan KM, Krauss RM (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82: 495–506Google Scholar
  6. Austin MA, Brunzell JD, Fitch WL, Krauss RM (1990) Inheritance of low density lipoprotein subclass pattern in familial combined hyperlipoproteinaemia. Arteriosclerosis 10: 520–530PubMedCrossRefGoogle Scholar
  7. Balfour JA, McTavish D, Heel RC (1990) Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40: 260–290Google Scholar
  8. Berndt J, Gaumert R, Still J (1978) Mode of action of lipid lowering agents clofibrate and BM15075 on cholesterol biosynthesis in rat liver. Atherosclerosis 30: 147–152PubMedCrossRefGoogle Scholar
  9. Blane GF (1987) Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 83 Suppl 5B: 26–36Google Scholar
  10. Brodie RR, Chasseaud LF, Elsom FF, Franklin ER, Taylor T (1976) Antilipidemic drugs: the metabolic fate of the hypolipidemic agent isopropy-[4’-(pchlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LE 178) in rats, dogs and man. Arzneimitteeforschung 26: 896–901Google Scholar
  11. Brown MS, Goldstein JL (1985) Drugs used in the treatment of hyperlipoproteinemia. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 827–845Google Scholar
  12. Brown MS, Dana SE, Goldstein JL (1974) Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 249: 789–796Google Scholar
  13. Canzler H, Bojanovski D (1980) Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias. Artery 8: 171–178PubMedGoogle Scholar
  14. Castillo M, Burgos C, Rodriguez-Vico F, Zafra MF, Garcia-Peregrin E (1990) Effects of clofibrate on the main regulatory enzymes of cholesterogenesis. Life Sci 46 (6): 397–403PubMedCrossRefGoogle Scholar
  15. Chan MK (1989) Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism 38: 939–945PubMedCrossRefGoogle Scholar
  16. Chicaud P, Demange J, Drouin P, Debry G (1984) Long term (18 months) effects of fenofibrate in hypercholesterolaemic subjects. Action du fenofibrate chez des enfants hypercholesterolemiques: recul de 18 mois. Presse Med 13: 417–419PubMedGoogle Scholar
  17. Committee of Principal Investigators (1978) A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart 10: 1069–1118Google Scholar
  18. Committee of Principal Investigators (1984) WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol. Lancet 2: 600–604Google Scholar
  19. Coronary Drug Project Research Group (1977) Gall bladder disease as a side effect of drugs influencing lipid metabolism. N Engl J Med 296: 1188–1190Google Scholar
  20. Cosentini R, Blasi F, Trinchera M, Sommariva D, Fasoli A (1989) Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate. Atherosclerosis 79: 253–255PubMedCrossRefGoogle Scholar
  21. Crouse JR, Parks JS, Schey HM, Kahl FR (1985) Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 26: 566–574PubMedGoogle Scholar
  22. Curtis LD, Dickson AC, Ling KLE, Betteridge J (1988) Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia. Br Med J 297: 173–175CrossRefGoogle Scholar
  23. Dairou F, Regy C (1986) Ciprofibrate multicentric study in 6812 hyperlipidemic patients. (Abstract) In: Proceedings of the 9th International Symposium on Drugs Affecting Lipid Metabolism, p 62Google Scholar
  24. Davignon J, Gascon B, Brossard D, Quidoz S, Leboeuf N, Lelorier J (1982) The use of ciprofibrate in the treatment of familial hyperlipidemias. In: Noseda G, Fragiacomo C, Fumagalli R, Paoletti R (eds) Lipoproteins and coronary atherosclerosis. Elsevier, Amsterdam, pp 213–221Google Scholar
  25. Davison C, Benziger D, Fritz A, Edelson J (1975) Absorption and disposition of 2[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methylpropanoic acid, WIN 35 833, in rats, monkeys, and men. Drug Metab Dispos 3: 520–524PubMedGoogle Scholar
  26. Desager JP, Harvengt C (1978) Clinical pharmacokinetic study of procetofene, a new hypolipidemic drug, in volunteers. Int J Clin Pharmacol Biopharm 16: 570–574PubMedGoogle Scholar
  27. East C, Bilheimer DW, Grundy SM (1988) Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 109: 25–32PubMedGoogle Scholar
  28. Fears R (1983) Pharmacological control of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. In: Sabine JR (ed) 3-Hydroxy-3-methylglutaryl coenzyme A reductase. CRC, Boca RatonGoogle Scholar
  29. Fisher WR (1983) Heterogeneity of plasma low density lipoproteins. Manifestations of the physiologic phenomenon in man, Metabolism 32: 283–291PubMedCrossRefGoogle Scholar
  30. Forland SC, Feng Y, Cutler RE (1990) Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol 30: 29–32PubMedGoogle Scholar
  31. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317: 1237–1245PubMedCrossRefGoogle Scholar
  32. Fruchart JC, Davignon J, Bard JM, Grothe AM, Richard A, Fievet C (1987) Effect of fenofibrate treatment on type III hyperlipoproteinemia. Am J Med 83 Suppl 5B: 71–74Google Scholar
  33. Gavish D, Oschry Y, Fainaru M, Eisenberg S (1986) Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia. Eur J Clin Invest 16: 61–68PubMedCrossRefGoogle Scholar
  34. Gaw A, Shepherd J (1990) Combination drug therapy for hyperlipidaemia. J Drug Dev 3 Suppl 1: 227–231Google Scholar
  35. Glueck CJ, Speirs J, Tracy T (1990) Safety and Efficacy of combined gemfibrozillovastatin therapy for primary dyslipoproteinemias. J Lab Clin Med 115: 603–609PubMedGoogle Scholar
  36. Gofman JW, Lindgren FT, Elliott HM, Mantz W, Hewitt J, Strisower B, Herring B (1950) The role of lipids and lipoproteins in atherosclerosis. Science 111: 166–171PubMedCrossRefGoogle Scholar
  37. Goodman DS, Noble RP, Dell RB (1973) The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man. J Clin Invest 52: 2646–2655PubMedCrossRefGoogle Scholar
  38. Griffin BA, Caslake MJ, Gaw A, Yip B, Packard CJ, Shepherd J (1992) Effects of cholestyramine and acipimox on subfractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects. Eur J Clin Invest 22: 383–390Google Scholar
  39. Grundy SM, Ahrens EH, Salen G (1972) Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13: 531–551PubMedGoogle Scholar
  40. Gugler R, Hartlapp J (1978) Clofibrate kinetics after single and mulitiple doses. Clin Pharmacol Ther 24: 432–438PubMedGoogle Scholar
  41. Hammond MG, Mengel MC, Warmke GL, Fisher WR (1977) Macromolecular dispersion of human plasma low density lipoprotein in hypertriglyceridemia. Metabolism 26: 231–242CrossRefGoogle Scholar
  42. Harvengt C, Heller F, Desager JP (1980) Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 7: 73–82PubMedGoogle Scholar
  43. Homberg JC, Abuaf N, Helmy-Khalil S, Biour M, Poupon R, Islam S, Darnis F, Levy VG, Opolon P, Beaugrand M, Toulet J, Danan G, Benhamou JP (1985) Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 5: 722–727PubMedCrossRefGoogle Scholar
  44. Houlston R, Quiney J, Watts GF, Lewis B (1988) Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia. J R Soc Med 81: 274–276PubMedGoogle Scholar
  45. Illingworth DR (1991) Fibric acid derivatives. In: Rifkind BM (ed) Drug treatment of hyperlipidemia. Dekker, New YorkGoogle Scholar
  46. Illingworth DR, O’Malley JP (1990) The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipidemia. Metabolism 39: 403–409PubMedCrossRefGoogle Scholar
  47. Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE (1982) Ciprofibrate in the therapy of type II hypercholesterolaemia. A double blind trial. Atherosclerosis 44: 211–221Google Scholar
  48. Janus ED, Grant S, Lintott CJ, Wardell R (1985) Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis 57: 249–266Google Scholar
  49. Kleinman Y, Eisenberg S, Oschry Y, Gavish D, Stein O, Stein Y (1985) Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy. J Clin Invest 75: 1796–1803Google Scholar
  50. Klosiewicz-Latoszek L, Nowicka G, Szostak WB, Naruszewicz M (1987) Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia. Atherosclerosis 63: 203–209Google Scholar
  51. Krauss RM (1987) Physical heterogeneity of apolipoprotein B-containing lipoproteins. In: Lippel K (ed) Proceedings of the workshop on lipoprotein heterogeneity. Government Printing Office Washington, pp 15–21 (NIH publication no 87–2646 )Google Scholar
  52. Krauss RM, Burke DJ (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23: 97–104PubMedGoogle Scholar
  53. Langer T, Levy RI (1968) Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279: 856–858PubMedCrossRefGoogle Scholar
  54. Leaf DA, Connor WE, Illingworth DR, Bacon SP, Sexton G (1989) The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double blind crossover study. JAMA 262: 3154–3160Google Scholar
  55. Lehtonen A, Viikari J (1981) Effect of procetofen on serum total cholesterol, triglyceride, and high density lipoprotein-cholesterol concentrations in hyperlipoproteinemia. Int J Clin Pharmacol Ther Toxicol 19: 534–538Google Scholar
  56. Levy RI, Fredrickson DS, Shulman R, Bilheimer DW, Breslow JL, Stone NJ, Lux SE, Sloan HR, Krauss RM, Herbert PN (1972) Dietary and drug treatment of primary hyperlipoproteinemia. Ann Intern Med 77: 267–294Google Scholar
  57. Lussier-Cacan S, Bard JM, Boulet L, Nestruck AC, Grothe AM, Fruchart JC, Davignon J (1989) Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis 78: 167–182PubMedCrossRefGoogle Scholar
  58. Malmendier CL, Delcroix C (1985) Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 55: 161–169PubMedCrossRefGoogle Scholar
  59. Manninen V, Elo O, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA (1988) Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260: 641–651Google Scholar
  60. Manttari M, Koskinen P, Manninen V, Huttunen JK, Frick MH, Nikkila EA (1990) Effect of gemfibrozil on the concentration and composition of serum lipoproteins. Atherosclerosis 81: 11–17PubMedCrossRefGoogle Scholar
  61. Maxwell RE, Nawrocki JW, Uhlendorf PD (1983) Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats. Atherosclersis 48: 195–203CrossRefGoogle Scholar
  62. McNamara DJ, Davidson NO, Fernandez S (1980) In vitro cholesterol synthesis in freshly isolated mononuclear cells of human blood: effect of in vivo administration of clofibrate and/or cholestyramine. J Lipid Res 21: 65–71PubMedGoogle Scholar
  63. Mitropoulos KA, Venkatesan S (1985) Membrane mediated control of reductase activity. In: Preiss B (ed) Regulation of HMG-CoA reductase. Academic, Orlando, pp 1–48Google Scholar
  64. Monk JP, Todd PA (1987) Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hyperlipidaemia. Drugs 33: 539–576Google Scholar
  65. Musliner TA, Krauss RM (1988) Lipoprotein subspecies and risk of coronary disease. Clin Chem 34 (8B): B78 — B83PubMedGoogle Scholar
  66. Needham L, Finnegan I, Housley MD (1985) Adenylate cyclase and a fatty acid spin probe detect changes in plasma membrane lipid phase separations induced by dietary manipulation of the cholesterol: phospholipid ratio. FEBS Lett 183: 81–86PubMedCrossRefGoogle Scholar
  67. Nestel PJ, Hunt D, Wahlqvist ML (1980) Clofibrate raises plasma apoprotein A-I and HDL-cholesterol concentrations. Atherosclerosis 37: 625–629PubMedCrossRefGoogle Scholar
  68. Newton RS, Krause BR (1986) Mechanisms of action of gemfibrozil: comparison of studies in the rat to clinical efficacy. In: Fears R, Levy RI, Shepherd J, Packard CJ, Miller NE (eds) Pharmacological control of hyperlipidaemia. Prous, Barcelona, pp 171–186Google Scholar
  69. O’Brien RI (1991) Cholesterol and coronary heart disease: consensus or controversy? Office of Health Economics, London (Studies of Current Health Problems No 98 )Google Scholar
  70. Okerholm RA, Keeley FJ, Peterson FE, Glazko AJ (1976) The metabolism of gemfibrozil. Proc R Soc Med 69: 11–14PubMedGoogle Scholar
  71. Olsson AG, Oro L (1982) Dose—response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 42: 229–243PubMedCrossRefGoogle Scholar
  72. Olsson AG, Lang PD, Vollmar J (1985) Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. Atherosclerosis 55: 195–203PubMedCrossRefGoogle Scholar
  73. Packard CJ, Clegg RJ, Dominiczak MH, Lorimer AR, Shepherd J (1986) Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J Lipid Res 27: 930–938PubMedGoogle Scholar
  74. Palmer RH (1987) Effects of fibric acid derivatives on biliary lipid composition. Am J Med 83 Suppl 5B: 37–43Google Scholar
  75. Pierce LR, Wysowski DK, Gross TP (1990) Myopathy and rhabdomyolysis associated with lovastatin—gemfibrozil combination therapy. JAMA 264: 71–75Google Scholar
  76. Rabkin SW, Hayden M, Frohlich J (1988) Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial. Atherosclerosis 73: 233–240Google Scholar
  77. Rouffy J, Chanu B, Bakir F, Djian F, Goy-Loeper J (1985) Comparative evaluation of the effects of cipofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis 54: 273–281PubMedCrossRefGoogle Scholar
  78. Saku K, Gartside PS, Hynd BA (1985) Mechanism of gemfibrozil action on lipoprotein metabolism. J Clin Invest 75: 1702–1712PubMedCrossRefGoogle Scholar
  79. Schifferdecker E, Rosak C, Schoffling K (1984) Long term treatment with the lipid lowering agent ciprofibrate. Inn Med 11: 107–112Google Scholar
  80. Schneider A, Stange EF, Ditschuneit HH, Ditschuneit H (1985) Fenofibrate treatment inhibits HMG CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 56: 257–262PubMedCrossRefGoogle Scholar
  81. Shen MS, Krauss RM, Lindgren FT, Forte TM (1981) Heterogeneity of serum low density lipoproteins in normal human subjects. J Lipid Res 22: 236–244PubMedGoogle Scholar
  82. Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG, Lawrite TDV (1984) Apolipoprotein A and B (Sf 100–400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 74: 2164–2177PubMedCrossRefGoogle Scholar
  83. Shepherd J, Caslake MJ, Lorimer AR, Valiance BD, Packard CJ (1985) Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 5: 162–165PubMedCrossRefGoogle Scholar
  84. Shepherd J, Griffin B, Caslake M, Gaw A, Packard C (1991) The influence of fibrates on lipoprotein metabolism. Atheroscler Rev 22: 163–169Google Scholar
  85. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J (1990) Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 85: 193–202PubMedCrossRefGoogle Scholar
  86. Stahlberg D, Reihner E, Ewerth S, Einarsson K, Angelin B (1991) Effects of bezafibrate on hepatic cholesterol metabolism. Eur J Clin Pharmacol 40 Suppl 1: S33 — S36Google Scholar
  87. Stange EF, Fruhholz M, Osenbrugge M, Reimann F, Ditschuneit H (1991) Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells. Eur J Clin Pharmacol 40 Suppl 1: S37 — S40Google Scholar
  88. Steinmetz J, Morin C, Panek E, Siest G, Drouin P (1981) Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chim Acta 112: 43–53PubMedCrossRefGoogle Scholar
  89. Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J (1982) Effects of bezafibrate on receptor mediated and receptor independent low density catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 44: 355–364PubMedCrossRefGoogle Scholar
  90. Thompson GR (1989) Drug treatment of hyperlipidaemia. In: A handbook of hyperlipidaemia. Current Science, London, pp 177–194Google Scholar
  91. Thorp JM (1963) An experimental approach to the problem of disordered lipid metabolism. J Atheroscler Res 3: 351–360PubMedCrossRefGoogle Scholar
  92. Todd PA, Ward A (1988) Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 36: 314–339Google Scholar
  93. Vega GL, Grundy SM (1989) Comparison of lovastatin and gemfibrozil in nor-molipidemic patients with hypoalphalipoproteinemia. JAMA 262: 3148–3153Google Scholar
  94. Vessby B, Lithell H (1990) Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Atherosclerosis 82: 137–143PubMedCrossRefGoogle Scholar
  95. Wheeler KAH, West RJ, Lloyd JK, Barley J (1985) Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 60: 34–37PubMedCrossRefGoogle Scholar
  96. Wysowski DK, Kennedy DL, Gross TP (1990) Prescribed use of cholesterol lowering drugs in the United States, 1978 through 1988. JAMA 263: 2185–2188PubMedCrossRefGoogle Scholar
  97. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60: 473–485PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • A. Gaw
  • C. J. Packard
  • J. Shepherd

There are no affiliations available

Personalised recommendations